Kalshi plans to expand its prediction-market betting into biotech by offering “sports-style” wagers on clinical trial and regulatory outcomes. The platform says the move helps isolate binary events—like whether Phase 3 results succeed or whether the FDA approves a medicine—from broader stock swings. Kalshi is launching a limited set of biotech contracts in partnership with AppliedXL, starting with markets tied to Phase 3 trials from established drug makers and with full FDA decision dates. Critics warn about incentives and insider-trading risks, though Kalshi says it plans guardrails.
Published by Banx Network. This article is part of the Banx decentralized media programme, powered by the BXE token on the XRP Ledger.
